Healthcare News by GLG Council Members

What can people do to reduce their carbon footprint?

March 11, 2010

Analysis by: GLG Expert Contributor

Analysis of:Myriad Licenses Rights to Pancreatic Cancer Gene Patents | councils.glgroup.com

people should do something to reduce their carbon footprint.

What are the components of a low-carbon lifestyle?

March 11, 2010

Analysis by: GLG Expert Contributor

Analysis of:Myriad Licenses Rights to Pancreatic Cancer Gene Patents | councils.glgroup.com

We need a low-carbon life.

m-health sector’s healthy opportunities? - Same old claims, same old problems

March 10, 2010

Analysis by: GLG Expert Contributor

Analysis of:Healthy opportunities in the m-health sector | www.telecoms.com

There is once again much focus on the opportunities presented by the m-health market. Claims that m-health will revolutionise affordable healthcare delivery to all have been heard before with e-health, tele-care and tele-medicince. Where these initiatives did not live up to expectation will m-health be any different?Ade Bamigboye, CEO Mobile Flowwww.mobile-flow.com

Brucellosis in India: a deceptive infectious disease

March 10, 2010

Analysis by: GLG Expert Contributor

Analysis of:Brucellosis in India | http

Brucellosis is an important but neglected disease in India. This zoonotic disease is present in alllivestock systems and the increased demand for dairy products accompanied with changing andintensified farming practices has raised the concern for increased spread and intensifiedtransmission of this infection to the human population with increased risk of disease. Brucellosiscan be controlled by mass vaccination of livestock. Human brucellosis can be treated with acombination of antibiotics but is very difficult to diagnose and requires laboratory testing forconfirmation. Only a few recent studies have addressed the prevalence and importance of brucellosisas a human disease problem in India. The disease may be overlooked and misdiagnosed because ofthe difficult diagnosis and the absence and lack of experience with laboratory testing. Alertness ofmedical staff is needed to recognize and diagnose the disease. Awareness of risk groups is neededto take appropriate preventive measures and to accept control measures.

GSK withdraws sNDA for Avodart as prostate cancer chemopreventative drug

March 10, 2010

Analysis by: GLG Expert Contributor

Analysis of:GSK withdraws sNDA for prostate cancer drug Avodart | www.pharmabiz.com

Dutastaride (Avodart) has been used for treatment of symptomatic benign prostatic hypertrophy.  It has been shown effective in reducing prostate volume, symptoms related to prostatic enlargement and PSA blood levels. Based on earlier data showing efficacy in prevention of prostate cancer development using 5 alpha-reductase inhibitors, a trial of dutastaride was undertaken.Chemoprevention using dutasteride: the REDUCE trial Curr Opin Urol. 2005 Jan;15(1):29-32www.ncbi.nlm.nih.gov/pubmed/15586026

Taspoglutide may have the highest potential of sales amongst GLP-1

March 9, 2010

Analysis by: GLG Expert Contributor

Analysis of:Roche's phase-III trial of taspoglutide meets primary endpoint in reduction of blood glucose | www.pharmabiz.com

With all the recent data on Victoza(liraglutide) and C-cell hyperplasia and medullary thyroid cancer, and safety signal on Byetta LAR being further investigated which may

Ken PowellPresidentGenesis Business Development, LLC

Quest Launches OVA1 Test for Ovarian Cancer

March 9, 2010

Quest Diagnostics announced today that OVA1, the first FDA cleared test to help in the pre-surgical evaluation of women with an ovarian mass is now available exclusively through Quest on a national basis.  The OVA1 test is one of a handful of FDA cleared In Vitro Diagnostics Multi-Variant Index Assays (IVDMIAs).

Trend towards smaller EMR providers

March 9, 2010

Analysis by: GLG Expert Contributor

Analysis of:The next tech goldmine: Medical records | money.cnn.com

Traditionally, larger EMR vendors were thought to have advantages over smaller providers For smaller practices, a smaller EMR vendor may be more attractive because of price and infrastructure There should be a large push in 2010 for small practices to adopt EMR's because of the government incentives available in 2011

Ken PowellPresidentGenesis Business Development, LLC

Mindray Medical International to Offer New Shares

March 9, 2010

Mindray Medical International , a global medical technology company intends to offer 4 million new American depository shares (ADSs) at a price of $38.20 per ADS. 

Order in the Health Court!

March 5, 2010

Analysis by: GLG Expert Contributor

Analysis of:Health Courts Could Become Tort Reform Option | www.healthleadersmedia.com

To demonstrate an effort to be bipartisan in health care reform, President Obama this past week proposed up to $50 million to fund alternative demonstration projects, such as health courts, for resolving medical liability actions. A nonpartisan group called the Common Good, funded by the Robert Wood Johnson Foundation, has been working the past eight years with the Harvard School of Public Health and others to develop a proposal for how the U.S. could establish a health court system.

Page : 12345678910Next1 to 10 of 8065